Thomas G. Gant completed undergraduate studies at Wayne State University, MI, and doctoral studies at Colorado State University. Postdoctoral studies were carried out at Harvard University, MA, under the mentorship of Nobel laureate Professor E. J. Corey. His professional career in drug discovery and DKIE applications to medicines began at Pfizer (1995), moving then to Millennium Pharmaceuticals, leading the chemistry efforts for the Velcade backup. He then became the Scientific Founder (2004) and CSO of Auspex Pharmaceuticals, completing the first clinical trial to directly demonstrate a substantial kinetic isotope effect of a deuterated drug (SD-254) in humans. He is currently Associate Professor and Director of Pharmacy Post-Baccalaureate studies at Lake Erie College of Osteopathic Medicine, PA, and is President of the pharmaceutical consulting firm Recondite Falls Discovery, LLC.